What is ICD-10 code C92.41?

C92.41 is the ICD-10-CM diagnosis code for Acute promyelocytic leukemia, in remission. A rapidly developing blood cancer with abnormal promyelocytes that is currently in remission. It belongs to the ICD-10-CM chapter for neoplasms (c00-d49). C92.41 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. C92.41 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. C92.41 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. C92.41 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

What is the V28 vs V24 difference for C92.41?

CMS phased in the V28 risk adjustment model over payment years 2024 (33%), 2025 (67%), and 2026 (100%), replacing V24. V28 consolidates HCC categories, removes some lower-acuity conditions, and recalibrates RAF weights across the entire model. For C92.41, V28 maps to Colorectal, Bladder, and Other Cancers at RAF 0.000 while V24 mapped to Metastatic Cancer and Acute Leukemia at RAF 2.484. Both models can still appear in legacy data and in payer-specific lookback periods.

What should coders know when reporting C92.41?

Acute promyelocytic leukemia (APL) is a medical emergency; verify remission status is documented This subtype often responds well to targeted therapy; document treatment response Because C92.41 maps to a payment HCC, the documentation must also satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's risk adjustment score.

C92.41 ICD-10 Code: Acute promyelocytic leukemia

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC92.41Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C92.41

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Acute promyelocytic leukemia, in remission

A rapidly developing blood cancer with abnormal promyelocytes that is currently in remission.

Buddy Insight

Acute promyelocytic leukemia in remission indicates successful response to ATRA-based therapy, which is achievable in over 90% of patients who survive the initial high-risk DIC period.

CMS-HCC V28

Mapped

HCC 22

Colorectal, Bladder, and Othe...

RAF 0.0

CMS-HCC V24

Mapped

HCC 8

Metastatic Cancer and Acute L...

RAF 2.484

ACA/HHS

Not risk-adjusted for this model/period.

RAF 0

ESRD/PACE

Mapped

HCC 8

Metastatic Cancer and Acute L...

RAF 0.0

RXHCC

Mapped

HCC 21

Hodgkin Lymphoma and Other Ca...

RAF 0.0

Code Trumping

Basket needed

Compare selected patient codes to show trumped or trumps impact.

Code Book Path

Official

C92Myeloid leukemia

C92.4Acute promyelocytic leukemia

C92.41Acute promyelocytic leukemia, in remission

Inclusion Terms

Official

AML M3
AML Me with t(15;17) and variants

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for C92.41 in this effective period.

Related Child Codes

Official

C92.40Acute promyelocytic leukemia, not having achieved remission

C92.42Acute promyelocytic leukemia, in relapse

Includes

Official

ICD-10-CM does not list Includes notes for C92.41 in this effective period.

Excludes 1

Official

ICD-10-CM does not list Excludes 1 notes for C92.41 in this effective period.

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for C92.41 in this effective period.

Use Additional

Official

ICD-10-CM does not list Use Additional Code instructions for C92.41 in this effective period.

Code Also

Official

ICD-10-CM does not list Code Also instructions for C92.41 in this effective period.

Buddy Documentation Tip

HCC Buddy guidance

Documentation must confirm the PML-RARA-positive diagnosis and explicit remission status, ideally with molecular remission (undetectable PML-RARA by RT-PCR).

The treatment regimen (ATRA/arsenic trioxide or ATRA/chemotherapy), date of remission, and consolidation/maintenance plan should be recorded.

Molecular monitoring schedule during post-consolidation surveillance must be documented, typically every 3 months for 2 years.

MEAT Support

HCC Buddy guidance

Documentation must confirm the PML-RARA-positive diagnosis and explicit remission status, ideally with molecular remission (undetectable PML-RARA by RT-PCR).

The treatment regimen (ATRA/arsenic trioxide or ATRA/chemotherapy), date of remission, and consolidation/maintenance plan should be recorded.

Molecular monitoring schedule during post-consolidation surveillance must be documented, typically every 3 months for 2 years.

Audit Caution

HCC Buddy guidance

Distinguish between hematologic remission (normalized counts, less than 5% blasts) and molecular remission (undetectable PML-RARA).

Molecular remission is the treatment goal in APL.

Patients completing ATRA/arsenic trioxide with molecular remission may eventually be considered cured, but ongoing surveillance is required for at least 2 years.

Do not stop coding APL until the monitoring period is complete and the provider confirms the disease is resolved.

Common Mistakes

HCC Buddy guidance

C92.40 (APL not in remission) is for active disease.

C92.42 (APL in relapse) is for recurrent disease.

C92.01 (AML in remission) is less specific and does not capture the APL subtype with its distinct treatment implications.

Z85.6 (personal history of leukemia) should not be used during the active molecular monitoring period.

Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.

Is C92.41 an HCC code?

Yes. C92.41 maps to Colorectal, Bladder, and Other Cancers under the CMS-HCC V28 risk adjustment model (and Metastatic Cancer and Acute Leukemia under V24).

HCC Category Mapping

V28HCC 22, Colorectal, Bladder, and Other Cancers

0.000

V24HCC 8, Metastatic Cancer and Acute Leukemia

2.484

ESRDHCC 8, Metastatic Cancer and Acute Leukemia

0.000

RxHCCHCC 21, Hodgkin Lymphoma and Other Cancers

0.000

RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

MEAT Criteria for C92.41

For C92.41to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C92.41 during that encounter, not just copy-forwarded from a problem list.

What This Code Means

C92.41 is the ICD-10-CM diagnosis code for acute promyelocytic leukemia, in remission. A rapidly developing blood cancer with abnormal promyelocytes that is currently in remission. C92.41 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C92.41 maps to Colorectal, Bladder, and Other Cancers (HCC 22) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, C92.41 maps to Metastatic Cancer and Acute Leukemia (HCC 8) with a community, non-dual, aged base RAF weight of 2.484. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Acute promyelocytic leukemia (APL) is a medical emergency; verify remission status is documented. Because C92.41 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C92.41 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Acute promyelocytic leukemia (APL) is a medical emergency; verify remission status is documented
•This subtype often responds well to targeted therapy; document treatment response

Clinical Significance

Acute promyelocytic leukemia in remission indicates successful response to ATRA-based therapy, which is achievable in over 90% of patients who survive the initial high-risk DIC period. Remission in APL is typically assessed by molecular testing showing undetectable PML-RARA transcripts by PCR. APL has the highest cure rate among AML subtypes, and patients achieving molecular remission after consolidation have excellent long-term outcomes.

Documentation Requirements

✓Documentation must confirm the PML-RARA-positive diagnosis and explicit remission status, ideally with molecular remission (undetectable PML-RARA by RT-PCR).
✓The treatment regimen (ATRA/arsenic trioxide or ATRA/chemotherapy), date of remission, and consolidation/maintenance plan should be recorded.
✓Molecular monitoring schedule during post-consolidation surveillance must be documented, typically every 3 months for 2 years.

Commonly Confused Codes

•C92.40 (APL not in remission) is for active disease.
•C92.42 (APL in relapse) is for recurrent disease.
•C92.01 (AML in remission) is less specific and does not capture the APL subtype with its distinct treatment implications.
•Z85.6 (personal history of leukemia) should not be used during the active molecular monitoring period.